Clinical and Immunological Outcome in High-risk Resected 1 Melanoma Patients Receiving Peptide-based Vaccination and 2 Interferon Alpha, with or without Dacarbazine Preconditioning: a 3 Phase II Study

Autor: Urbani F., Ferraresi V, Capone I., Macchia I., Palermo B., Nuzzo C., Torsello A., Pezzotti P., Giannarelli D., Pozzi A.F., Santaquilani M., Roazzi P., Bastucci S., Catricalà C., La Malfa A., Vercillo G., Gualtieri N., Buccione C., Castiello L., Cognetti F., Nisticò P., Belardelli F., Moschella F., Proietti E

Publikováno v: Frontiers in oncology (2020). doi:10.3389/fonc.2020.00202
info:cnr-pdr/source/autori:Urbani F., Ferraresi V, Capone I., Macchia I., Palermo B., Nuzzo C., Torsello A., Pezzotti P., Giannarelli D., Pozzi A.F., Santaquilani M., Roazzi P., Bastucci S., Catricalà C., La Malfa A., Vercillo G., Gualtieri N., Buccione C., Castiello L., Cognetti F., Nisticò P., Belardelli F., Moschella F., Proietti E/titolo:Clinical and Immunological Outcome in High-risk Resected 1 Melanoma Patients Receiving Peptide-based Vaccination and 2 Interferon Alpha, with or without Dacarbazine Preconditioning: a 3 Phase II Study/doi:10.3389%2Ffonc.2020.00202/rivista:Frontiers in oncology/anno:2020/pagina_da:/pagina_a:/intervallo_pagine:/volume

Clinical studies based on novel rationales and mechanisms of action of chemotherapy agents and cytokines can contribute to the development of new concepts and strategies of antitumor combination therapies. In previous studies, we investigated the par

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::77f1d87cd155dae9d9b018c2d95edfc2